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Comparison of Visceral Fat and Liver Fat as Risk Factors of 
Metabolic Syndrome
The principal objective of this study was to determine whether visceral fat or liver fat is a 
more relevant risk factor for metabolic syndrome. A total of 98 subjects aged 18-65 yr, 
who visited a health promotion center in a university hospital, were enrolled in this study. 
Metabolic syndrome was diagnosed based on the modified National Cholesterol Education 
Program’s Adult Treatment Panel III report (NCEP-ATPIII) criteria. We defined the visceral 
obesity as a visceral fat area of  ≥ 100 cm
2 which was acquired by CT at the L4-5 level. To 
evaluate fatty liver, we applied a liver-to-spleen attenuation ratio ≤ 1.1 as measured by CT 
at the T12 level. We employed binary logistic regression models that used the presence or 
absence of metabolic syndrome as a dependent variable and age, sex, and the presence or 
absence of visceral obesity and fatty liver as independent variables. Visceral obesity was not 
found to be an independent variable as a risk factor of metabolic syndrome (odds ratio 2.7; 
95% confidence interval 0.55-13.30), but fatty liver was found to be significant in this 
model (odds ratio 71.3; 95% CI 13.04-389.53). Our study suggests that liver fat may be a 
more important risk factor than visceral fat in terms of its association with metabolic 
syndrome.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) has been recognized 
as a feature of insulin resistance. Recent evidence supports the 
notion that NAFLD is associated with a number of systemic dis-
eases, including visceral obesity, cardiovascular disease, type 2 
diabetes, and metabolic syndrome. This association has been 
attributed to increased cardiovascular mortality and morbidity 
(1-3). On the basis of liver biopsy results, Marchesini et al. (4) re-
ported that nondiabetic patients with metabolic syndrome ex-
hibited more severe fibrosis and inflammation in the liver, re-
gardless of age, sex and body mass index (BMI), than those pa-
tients without metabolic syndrome. The diagnosis of NAFLD 
was rendered on the basis of liver biopsy, but computed tomog-
raphy (CT) has been reported to provide a more objective eval-
uation, which is reproducible and correlated more closely with 
fat accumulation in the liver (5, 6).
  Visceral fat is independently related to morbidity and mortal-
ity of the coronary heart disease and associated with metabolic 
syndrome, diabetes, and cardiovascular disease. Because of this, 
visceral fat has been employed as a clinical measure of risk for 
obesity (7, 8). Recently, Kantartzis et al. (9) reported that liver fat 
was a more relevant independent factor for glucose metabolism 
than visceral fat. Thus far, the impact of liver fat versus visceral 
fat in determining metabolic syndrome has not been investigat-
ed in any detail. Therefore, in this study we attempted to deter-
mine which of these fats as measured by CT was more closely 
associated with metabolic syndrome.
MATERIALS AND METHODS
Participants
We conducted a retrospective analysis using medical records. A 
total of 98 subjects (34 males, 64 females) aged 18-65 yr, who vis-
ited a health promotion center in a university hospital for regu-
lar health check-up and underwent visceral fat CT from Septem-
ber 2007 to June 2010 were enrolled in this study. According to 
the questionnaire responses, those with a history of consuming 
more than 40 g alcohol per week, or chronic liver disease were 
excluded. Additionally, those who were positive to the superfi-
cial antigen of hepatitis B (HBsAg) or hepatitis C antibody were 
also excluded. 
Anthropometry
Height and weight were measured with the subject wearing only 
a gown, and having fasted for more than 12 hr. We measured up 
to 0.1 kg, 0.1 cm automatically (HM-170, Fanics, Korea) and con-
ducted a body composition analysis using Inbody720 fat analyzer Lee J, et al.  •  Comparison of Visceral Fat and Liver Fat
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(Biospace Co., Seoul, Korea). Waist circumference was mea-
sured at the midline between the lowest rib and the upper part 
of the iliac crest, according to WHO guidelines (10).
The measurement of visceral fat area (VFA)
Visceral fat area was measured by single-slice CT (SOMATOM 
Plus4, Siemens, Erlangen, Germany) at the 4-5th level of lum-
bar vertebrae using an attenuation range of 30 to -190 Hounsfield 
units (HU). We defined visceral obesity as a visceral fat area of 
more than 100 cm
2 (11).
Measurement of liver fat accumulation
To quantify the accumulation of liver fat, we obtained the mean 
liver attenuation from an average of 4 selected areas of approxi-
mately 200 mm
2 each, including the right-anterior lobe, right-
posterior lobe, and left-interior lobe of the liver, at the T12 level. 
We also obtained the mean spleen attenuation from an average 
of 2 areas of the spleen (anterior and posterior pole) at the T12 
level. Finally, we calculated the liver-to-spleen attenuation ratio 
(LSR), and fatty liver was defined as an LSR  ≤ 1.1 (12, 13) (Fig. 1).
Evaluation of metabolic risk factors
All subjects underwent blood sampling after fasting for 12 hr. 
Using an automatic blood pressure monitor (FT500-R, Jawon 
medical Co. LTD., Kyoungsan-City, Kyongsang Buk-do, Korea), 
we measured blood pressure in sitting position in the left arm, 
after the patient had rested for at least 5 min. Blood glucose, total 
cholesterol, triglyceride, high-density lipoprotein (HDL) and low-
density lipoprotein (LDL) cholesterol were determined using a 
chemistry immunoanalyzer (Olympus Au5400 Olympus Opti-
cal, Tokyo, Japan). Serum insulin was measured using a human 
insulin specific radioimmunoassay kit (Linco Research Inc., St. 
Charles, MO, USA). Insulin sensitivity was evaluated by calcu-
lating the Homeostasis model assessment for insulin resistance 
(HOMA–IR) index {(fasting insulin [μU/mL] × fasting blood glu-
cose mM)/22.5}. Smoking status was defined as a current smok-
er or a non-smoker who had stopped smoking within the last 6 
months.
Diagnosis of metabolic syndrome
Diagnosis of metabolic syndrome was rendered in accordance 
with the National Cholesterol Education Program’s Adult Treat-
ment Panel III report (NCEP-ATPIII) criteria with the exception 
of waist circumference (14). Diagnosis of metabolic syndrome 
required at least two of the following: triglyceride  ≥ 150 mg/dL 
(1.7 mM), HDL-cholesterol < 40 mg/dL (1.03 mM) in men, < 50 
mg/dL (1.29 mM) in women, blood pressure systolic  ≥ 130 mmHg 
or diastolic  ≥ 85 mmHg, fasting blood glucose  ≥ 100 mg/dL 
(5.6 mM).
Statistical analysis
Data were expressed as means ± standard deviation. Consider-
ing the characteristics of the variables, independent t-tests and 
Pearson chi-square tests were carried out in order to evaluate 
the differences between the metabolic syndrome group and the 
non-metabolic syndrome group. To determine the predictive 
effects of visceral fat and liver fat as risk factors for metabolic 
syndrome, binary logistic regression analyses were carried out. 
In this model, the presence of metabolic syndrome was a depen-
dent variable, and age, sex, the presence of visceral obesity and 
the presence of fatty liver as measured by LSR were independent 
variables. P values of less than 0.05 were considered significant. 
PASW Statistics 18 statistical software (SPSS Inc., Chicago, IL, 
USA) was used for the analysis.
Ethics statement
This study protocol was reviewed and approved by institutional 
review board of Konyang University Hospital (research number: 
11-32). Written informed consent was obtained from subjected 
patients. 
 
RESULTS
Demographic and clinical characteristics according to the 
presence of metabolic syndrome
The 98 participants in this study, 34 men and 64 women, had a 
mean age of 39.4 ± 13.6 yr (men, 41 ± 13.1 yr; women, 38.4 ±  
13.8 yr). The prevalence of metabolic syndrome was 33.7% over-
all. Average age of the subjects with metabolic syndrome (45.1 ±  
12.1 yr) was significantly higher than that of the subjects with-
out metabolic syndrome (36.9 ± 13.6 yr) (P = 0.004) (Table 1). 
BMI was significantly higher in the metabolic syndrome group 
(P = 0.021), but body fat percentage (body fat %) did not differ 
significantly between the two groups (31.0% ± 6.0%, 31.4% ±  
6.7%, respectively). Visceral adipose tissue (VAT) was significant-
ly higher in the metabolic syndrome group (113.4 ± 39.5 cm
2) 
Fig. 1. Abdominal fat CT for measurement of liver and spleen attenuation (in Houn-
sfield units).Lee J, et al.  •  Comparison of Visceral Fat and Liver Fat
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than the non-metabolic syndrome group (76.5 ± 26.9 cm
2) (P <  
0.001). CT attenuations values of each liver and spleen varied sig-
nificantly, and LSR also showed significant difference between 
the two groups (P < 0.001). The two groups differed significant-
ly in terms of blood pressure, fasting blood glucose, triglyceride, 
HDL-cholesterol, and LDL-cholesterol, but not in total choles-
terol (P = 0.125). HOMA-IR was 3.6 ± 1.4 in the metabolic syn-
drome group, and 2.5 ± 1.2 in the non-metabolic syndrome 
group, and this difference reached significance (P < 0.001). No 
differences in liver enzymes (aspartate aminotransferase, ala-
nine aminotransferase and γ-glutamyltransferase) were detect-
ed between the two groups. The smoking rate was significantly 
higher in the subjects with metabolic syndrome (36.4%, 12/33) 
than in the subjects without metabolic syndrome (9.2%, 6/65) 
(P = 0.01) (Table 1).
Prevalence of metabolic risk factors
The prevalence of hypertriglyceridemia was 27.6% (men 44.1%, 
women 18.8%). 30.6% of total subjects (men, 20.6%; women, 
35.9%) had low HDL-cholesterol. High blood pressure and hy-
perglycemia were noted in 26.5% (men, 50.0%; women, 14.1%) 
and 27.6% (men, 41.2%; females, 20.3%) respectively. The prev-
alence of metabolic syndrome defined as a cluster of at least two 
metabolic risk factors was 33.7% of the total subjects (men, 47.1%; 
women, 26.6%) (Table 2).
Comparison of the metabolic risk factors according to the 
liver to spleen ratio and the visceral fat area
Subjects with fatty liver (defined as LSR ≤ 1.1) exhibited signifi-
cantly higher waist circumference (P < 0.001), systolic blood 
pressure (P = 0.002), diastolic blood pressure (P < 0.001), fast-
ing blood glucose (P = 0.029), triglycerides (P < 0.001) and 
HOMA-IR (P < 0.001) than subjects without fatty liver. HDL-
cholesterol levels were significantly lower in the subjects with 
fatty liver (P <  0.001) (Fig. 2). Subjects with visceral abdominal 
obesity (defined as VFA ≥ 100 cm
2) also had significantly higher 
waist circumference (P < 0.001), systolic blood pressure (P =  
0.018), diastolic blood pressure (P = 0.002), fasting blood glu-
cose (P = 0.042), and triglycerides (P < 0.001) than subjects 
without visceral obesity. HDL-cholesterol levels were lower in 
the group with visceral obesity (P = 0.006). However, HOMA-IR 
did not differ significantly regardless of presence of visceral 
obesity (P = 0.077) (Fig. 2).
Comparison between visceral fat and liver fat as risk 
factors of metabolic syndrome
Binary logistic regression analyses were carried out to compare 
visceral obesity (VFA ≥ 100 cm
2) and fatty liver (LSR ≤ 1.1) as risk 
factors of metabolic syndrome. In these models, the presence or 
absence of metabolic syndrome was used as a dependent vari-
able and age, sex, and the presence or absence of visceral obesity 
and fatty liver as independent variables. There was no multi-col-
linearity problem among these explanatory variables (Table 3). 
  In the total subjects, fatty liver (defined as LSR ≤ 1.1) adjusted 
for age and sex was found to be a significant independent vari-
able as a risk factor for metabolic syndrome (odds ratio 71.3; 95% 
confidence interval 13.04-389.53; P < 0.001), but visceral obesity 
was not (odds ratio 2.7; 95% CI 0.55-13.30; P = 0.219) (Model 1). 
Table 1. Demographic and clinical characteristics according to presence of metabolic 
syndrome
Parameters
Overall  
(n = 98)
No MS  
(n = 65)
MS  
(n = 33)
P value
Demographics
   Age (yr)
   Sex, men, No. (%)
 
39.4 (13.6)
34 (34.7)
 
36.9 (13.6)
18 (27.7)
 
45.1 (12.1)
16 (48.5)
 
0.004
0.04*
Body composition
   Height (cm)
   Weight (kg)
   Waist circumference  
      (cm)
   BMI (kg/m
2)
   Body fat (%)
   L4-5 VAT (cm
2)
   Liver attenuation (HU)
   Spleen attenuation (HU)
   Liver/Spleen attenuation  
      ratio
 
162.0 (8.3)
66.8 (12.6)
83.6 (8.0)
 
25.3 (3.4)
31.4 (6.4)
88.7 (36.2)
58.0 (8.4)
53.9 (6.5)
1.09 (0.17)
 
161.4 (7.9)
64.7 (11.6)
81.5 (7.9)
 
24.7 (3.3)
31.1 (6.7)
76.5 (26.9)
59.3 (7.2)
51.9 (6.1)
1.15 (0.14)
 
169.2 (8.9)
70.7 (13.6)
87.7 (6.4)
 
26.4 (3.3)
31.0 (6.0)
113.4 (39.5)
55.7 (10.1)
57.8 (5.3)
0.97 (0.17)
  
0.3
0.024
< 0.001
 
0.021
0.96
< 0.001
0.047
< 0.001
< 0.001
Metabolic characteristics
   Systolic BP (mmHg)
   Diastolic BP (mmHg)
   Fasting plasma glucose  
      (mg/dL)
   Total cholesterol (mg/dL)
   Triglyceride (mg/dL)
   HDL cholesterol (mg/dL)
   LDL cholesterol (mg/dL)
   Insulin (IU/L)
   HOMA-IR
   AST (U/L)
   ALT (U/L)
   γ-GT (U/L)
   Smoking (%)
 
114.8 (13.5)
76.8 (10.8)
96.6 (14.1)
 
197.3 (38.7)
131.0 (69.8)
52.9 (12.7)
124.3 (28.5)
12.2 (5.3)
2.9 (1.4)
23.8 (10.2)
25.5 (17.7)
23.8 (31.1)
18.4
 
111.3 (11.9)
73.7 (9.4)
93.3 (7.1)
 
193.5 (41.0)
101.6 (46.7)
57.3 (12.4)
119.3 (29.6)
10.8 (4.5)
2.5 (1.2)
23.3 (11.6)
23.8 (19.0)
21.7 (36.6)
9.2
 
121.8 (13.7)
83.2 (10.7)
103.3 (20.8)
 
206.2 (32.9)
188.9 (71.2)
44.2 (7.6)
134.9 (23.4)
14.8 (5.1)
3.6 (1.4)
24.9 (6.4)
28.8 (14.3)
28.2 (14.1)
36.4
 
< 0.001
< 0.001
0.011
 
0.125
< 0.001
< 0.001
0.01
< 0.001
< 0.001
0.476
0.184
0.207
0.01*
Data are expressed as means (SD; standard deviation), independent t-test or chi-
square test*. BMI, body mass index; L4-5 VAT, visceral adipose tissue area at the 4th-
5th lumbar vertebral level; HU, Hounsfield unit; BP, blood pressure; HDL, high density 
lipoprotein; LDL, low density lipoprotein; HOMA-IR, homeostasis model assessment 
of insulin resistance; AST, aspartate aminotransferase; ALT, alanine aminotransferase; 
γ-GT, gamma-glutamyltransferase. 
Table 2. Prevalence of metabolic risk factors
Risk factors Total (n = 98) Men (n = 34) Women (n = 64)
Hypertriglyceridemia* 27 (27.6%) 15 (44.1%) 12 (18.8%)
Low HDL
† 30 (30.6%)   7 (20.6%) 23 (35.9%)
High BP
‡ 26 (26.5%) 17 (50.0%)   9 (14.1%)
Hyperglycemia
§ 27 (27.6%) 14 (41.2%) 13 (20.3%)
Metabolic syndrome 
   (risk factors  ≥ 2)
33 (33.7%) 16 (47.1%) 17 (26.6%)
*Hypertriglyceridemia defined as triglycerides ≥ 150 mg/dL; 
†Low HDL defined as HDL 
cholesterol < 40 mg/dL in men, < 50 mg/dL in women; 
‡High BP defined as systolic 
BP ≥ 130 mmHg or diastolic BP ≥ 85 mmHg; 
§Hyperglycemia defined as fasting plas-
ma glucose ≥ 100 mg/dL or previously diagnosed type 2 diabetes. HDL, high-density 
lipoprotein cholesterol; BP, blood pressure.Lee J, et al.  •  Comparison of Visceral Fat and Liver Fat
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Fig. 2. Comparison of the risk factor of metabolic syndrome according to the liver to spleen ratio (LSR) and the L4-5 visceral adipose tissue (VAT). P value from t-test. VAT, vis-
ceral adipose tissue area at the 4-5th lumbar vertebral level (cm
2); LSR, Liver to spleen attenuation ratio.
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Table 3. Binary logistic regression analysis for the presence of metabolic syndrome in the study subjects
Independent variables β Standard error P value Oddss ratio
95% confidence  
interval
R
2
Model 1 (Total)
   Sex
   Age
   L4-5 VAT
   LSR
 
0.93
0.05
0.99
4.27
 
0.78
0.03
0.81
0.87
 
0.232
0.113
0.219
< 0.001
 
2.53
1.05
2.71
71.26
 
0.55-11.56
0.99-1.12
0.55-13.30
13.04-389.52
0.674
Model 2 (Men)
   Age
   L4-5 VAT
   LSR
 
-0.01
1.89
2.79
 
0.05
1.16
1.20
 
0.762
1.103
0.020
 
0.99
6.62
16.30
 
0.90-1.08
0.68-64.12
1.56-170.92
0.510
Model 3 (Women)
   Age
   L4-5 VAT
   LSR
 
0.12
-0.07
8.82
 
0.06
1.53
1.55
 
0.031
0.962
< 0.001
 
1.13
0.93
338.4
 
1.01-1.26
0.05-18.79
16.36-7,002.80
0.784
Dependent variable: presence or absence of metabolic syndrome. Independent variables: sex, age, presence of visceral obesity with visceral adipose tissue area (VAT)  ≥ 100 cm
2, 
presence of fatty liver (LSR ≤ 1.1). L4-5 VAT, visceral adipose tissue area at the 4-5th lumbar vertebral level (cm
2); LSR, Liver to spleen attenuation ratio.
We observed the same results in the sex-sorted data: fatty liver 
was the only significant independent variable to explain meta-
bolic syndrome (Model 2 and 3).Lee J, et al.  •  Comparison of Visceral Fat and Liver Fat
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DISCUSSION
Recent studies have shown that although obesity is strongly as-
sociated with metabolic disorder, the site of fat accumulation is 
a more important risk factor for the metabolic disorder than obe-
sity itself. In this study, using the data of 98 participants who vis-
ited the health promotion center in a university hospital, we at-
tempted to determine whether visceral fat or liver fat was a more 
relevant risk factor for metabolic syndrome. The number of wom-
en participant in our study was almost double to that of men 
participants because much more number of men had history of 
alcohol which was one of the exclusion criteria. With regard to 
the smoking history, the group with metabolic syndrome con-
tained a significantly higher proportion of smokers than the group 
without metabolic syndrome (36.4% vs 9.2%, respectively; P =  
0.01). The effects of smoking on metabolic syndrome have been 
previously reported that smoking is the one of risk factors for 
insulin resistance (15-17). However, in our total study popula-
tion, significant independent variables to metabolic syndrome 
did not change after adjustment of smoking history during the 
logistic regression analysis.
  It has been shown that the prevalence of cardiovascular dis-
ease increases after the age of 40 in men and 50 in women, but 
the average age of the participants in this study was 39.4; this may 
be the reason that the men in this study had a higher prevalence 
of metabolic risk factors than the women in this study (Table 2).
  In the present study, fatty liver (defined as LSR ≤ 1.1) adjusted 
for age and sex was found to be a significant independent vari-
able as a risk factor for metabolic syndrome, but visceral obesity 
(defined as VFA ≥ 100 cm
2) was not. We obtained the same re-
sults in the sex-sorted data: fatty liver was the only significant 
independent variable. These findings are consistent with the 
recently reported data of Fan et al. (18), who determined that 
NAFLD was more relevant than obesity itself in determining 
metabolic syndrome. Despite the fact that liver fat or the pres-
ence of fatty liver was found to be closely associated with meta-
bolic disorders (prediabetes, diabetes, and hypertension) in 
many studies (9, 19-21), there have been no studies conducted 
specifically to compare the relevance of visceral fat and liver fat 
to metabolic syndrome as far as we know. Thus, our study may 
provide new insights into this issue.
  Ryysy et al. (22) reported previously that variations in hepatic 
fat content may affect insulin requirements via an effect on the 
sensitivity of endogenous glucose production to insulin in type 
2 diabetic patients with insulin therapy. Moreover, they demon-
strated that as more liver fat accumulates, it becomes more close-
ly associated with the insulin-resistance conditions, including 
hyperinsulinemia, hypertriglyceridemia, low HDL-cholesterol, 
and high systolic blood pressure. Seppälä-Lindroos et al. (23) 
reported that the accumulation of fat in the liver is, independent 
of body mass index and visceral obesity, characterized by sev-
eral features of insulin resistance in moderately overweight and 
normal-weight subjects. Although abdominal visceral fat was a 
correlate of increased systemic and splanchnic rates of lipolysis, 
upper body nonsplanchnic tissue was definitively shown to be 
the principal contributor to whole body lipolysis in a previous 
study examining the relationship among deep abdominal sub-
cutaneous fat, visceral fat, and glucose disappearance using the 
portal vein catheterization technique of Basu et al. (24). Despite 
the known association between visceral fat and insulin resis-
tance and metabolic disorders, our findings demonstrate that 
fat accumulation in insulin-sensitive tissues may be a more im-
portant determinant of insulin sensitivity than visceral fat itself. 
On the other hand, visceral fat levels tend to be lower in women 
than in men, and lower in young people than in older individu-
als. In this regard, because the proportion of women in the total 
subject population was high, the average patient age was 39.4 yr, 
and the average VFA was 88.7 cm
2, we are unable to exclude the 
possibility that our dataset had some effect on this result.
  This study suffered from several limitations. First of all, the 
cross-sectional nature of the study did not allow definitive con-
clusions about causal relationships to be drawn. Second, as men-
tioned earlier, because we enrolled only a total of 98 subjects 
and there was a sex-ratio imbalance in the subject population, 
these may have been influenced the outcome. Third, the results 
of the present study cannot be directly applied to general popu-
lations, because the study was designed for, and performed in, 
a limited population. Finally, the diagnostic criterion of fatty liver 
which was used in this study has its own limitation as a refer-
ence of standard.
  In conclusion, we found that liver fat was more associated 
with metabolic syndrome than visceral fat. Thus, NAFLD may 
be a more relevant risk factor for metabolic syndrome than is 
visceral obesity. 
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